PSTV.NASDAQPlus Therapeutics, INC
DEF 14A: Plus Therapeutics Aims to Expand Radiotherapeutic Pipeline, Seeks Stockholder Approval for Incentive Plan
Sentiment:
Proxy Statement
Plus Therapeutics is making strides in its targeted radiotherapeutic platform, seeking stockholder approval for an amended stock incentive plan to attract and retain key personnel.
Capital raiseIn May 2024, Plus Therapeutics entered into a securities purchase agreement with certain investors for the sale and issuance of its securities.The Purchase Agreement provides for the sale and issuance by the Company of an aggregate of 3,591,532 shares of the Company's Common Stock or, at the election of each purchaser, pre-funded warrants, with each Private Placement Share or Pre-Funded Warrant accompanied by (i) a Series A common warrant and (ii) one Series B common warrant.The aggregate gross proceeds at the May 2024 PIPE Financing closing were approximately $7.25 million, before deducting certain expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Series A Warrants, the Series B Warrants and Pre-Funded Warrants.
Summary
- Plus Therapeutics is focused on advancing its targeted radiotherapeutic platform, particularly rhenium (Re186) obisbemeda, for central nervous system cancers like leptomeningeal metastases (LM) and recurrent glioblastoma (rGBM).
- The ReSPECT-LM trial for LM therapy is expected to complete Phase 1 enrollment this year, supported by a $17.6 million grant and FDA Fast Track designation.
- Interim data from ReSPECT-LM showed safety, feasibility, and signs of tumor response.
- The company plans to initiate a Phase 1 multi-dose trial and potentially a Phase 2/3 single-dose registrational trial, pending FDA agreement.
- Plus Therapeutics acquired all rights to the CNSide assay for LM diagnosis, aiming to commercialize and partner the asset.
- The Phase 2 ReSPECT-GBM trial for rGBM is ongoing, with interim data showing safety, feasibility, and an efficacy signal favorable to the standard of care.
- Enrollment is expected to complete in the next few quarters, followed by a Phase 3 pivotal trial.
- An IND approval is planned to evaluate rhenium (Re186) obisbemeda in pediatric brain cancer (PBC), supported by a $3 million Department of Defense award.
- The company raised sufficient capital to fund plans through 2026.
- The company is seeking stockholder approval for the fourth amendment and restatement of the 2020 Stock Incentive Plan, increasing the share reserve by 1,000,000 shares.
Sentiment
Score: 7
Explanation: The document presents a generally positive outlook, highlighting progress in clinical trials, acquisitions, and funding. However, it also acknowledges risks and uncertainties associated with forward-looking statements, preventing a higher score.
Positives
- The ReSPECT-LM trial is expected to complete Phase 1 enrollment this year, backed by a $17.6 million grant.
- Interim ReSPECT-LM data showed safety, feasibility, and tumor response signs.
- The company acquired full rights to the CNSide assay for LM diagnosis.
- The ReSPECT-GBM Phase 2 trial is ongoing, with interim data showing favorable efficacy signals.
- An IND approval is planned for Re186 obisbemeda in pediatric brain cancer, supported by a $3 million award.
- The company raised sufficient capital to fund plans through 2026.
Risks
- The document mentions forward-looking statements that involve risks and uncertainties, which could cause actual results to differ materially from expected results.
- These risks are detailed in the Risk Factors section of the company's Annual Report on Form 10-K.
Future Outlook
The company plans to complete Phase 1 enrollment for the ReSPECT-LM trial, initiate a Phase 1 multi-dose clinical trial, and potentially start a Phase 2/3 single-dose registrational trial. They also plan to obtain an FDA IND approval to evaluate rhenium (Re186) obisbemeda in patients with pediatric brain cancer.
Management Comments
- Last year Plus Therapeutics made significant progress in advancing our targeted radiotherapeutic platform and strengthening our balance sheet.
- In 2024, we are poised to build on that progress and explore new opportunities aimed at adding significant value to our pipeline.
- We are off to a great start in 2024 and the future is bright for Plus Therapeutics!
Industry Context
The announcement reflects a broader trend in the pharmaceutical industry towards targeted radiotherapeutics, particularly for difficult-to-treat cancers like those in the central nervous system. The company's focus on LM and rGBM addresses unmet needs in oncology.
Comparison to Industry Standards
- Plus Therapeutics is developing targeted radiotherapeutics, similar to companies like Bayer with Xofigo and Novartis with Lutathera, but focusing on CNS cancers.
- The company's ReSPECT trials are comparable to other Phase 1 and Phase 2 oncology trials in terms of design and endpoints.
- The CNSide assay aims to improve LM diagnosis, addressing the underdiagnosis issue seen with current methodologies, similar to efforts by other diagnostic companies to improve cancer detection rates.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Medical Officer | Norman LaFrance, M.D. | NA | June 11, 2024 | Dr. LaFrance stepped down from his position |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment and Restatement of 2020 Stock Incentive Plan | The fourth amendment and restatement of the 2020 Stock Incentive Plan includes an increase in the number of shares available for issuance of equity incentive awards by the Company by 1,000,000 shares. | July 8, 2024 (subject to stockholder approval) | Aims to align the interests of directors, executives and employees with those of our stockholders and limits our ability to attract and retain talented personnel. |
Related Party Transactions
- In May 2024, certain of the Company's directors and executive officers (Company Insiders) participated in the May 2024 PIPE Financing.
- The Company Insiders participated in the Initial Subscription at an offering price of $2.04 per Private Placement Share and accompanying Series A Warrant and Series B Warrant.
Stakeholder Impact
- Shareholders: The company's progress in clinical trials and financial stability could positively impact shareholder value.
- Employees: The amended stock incentive plan aims to attract and retain key personnel, potentially benefiting employees.
- Patients: Advancements in radiotherapeutic treatments could provide new options for patients with CNS cancers.
Next Steps
- Complete Phase 1 enrollment for the ReSPECT-LM trial.
- Initiate a Phase 1 multi-dose clinical trial for LM therapy.
- Potentially start a Phase 2/3 single-dose registrational trial for LM therapy, pending FDA agreement.
- Present FORESEE clinical trial data at the 2024 SNO/ASCO CNS Metastases Conference.
- Complete enrollment in the Phase 2 ReSPECT-GBM trial.
- Proceed to a Phase 3 pivotal trial for rGBM.
- Obtain an FDA IND approval to evaluate rhenium (Re186) obisbemeda in patients with pediatric brain cancer (PBC).
- Stockholder vote on the fourth amendment and restatement of the 2020 Stock Incentive Plan.
Key Dates
| Date | Description |
|---|---|
| December 29, 2015 | Adoption of the 2015 New Employee Incentive Plan |
| July 2016 | BDO USA, P.C. became the independent registered public accounting firm |
| June 16, 2020 | Stockholders approved the Plus Therapeutics, Inc. 2020 Stock Incentive Plan |
| April 1, 2020 | Howard Clowes and Robert Lenk joined the Board |
| February 2020 | Andrew Sims joined as Chief Financial Officer and Greg Petersen joined the Board |
| January 1, 2020 | An van Es-Johansson joined the Board |
| May 13, 2020 | Amended and Restated Executive Employment Agreements with Dr. Hedrick and Mr. Sims |
| May 17, 2021 | Stockholders approved the amended and restated 2020 Stock Incentive Plan |
| May 16, 2022 | Stockholders approved the second amended and restated 2020 Stock Incentive Plan |
| April 20, 2023 | Stockholders approved the third amended and restated 2020 Stock Incentive Plan |
| February 17, 2023 | Each non-employee director was awarded a grant of options for 20,182 shares as equity compensation |
| May 2024 | Entered into a securities purchase agreement for the sale and issuance of securities |
| May 8, 2024 | Entered into a first amendment to the Securities Purchase Agreement |
| June 7, 2024 | Filed with the SEC a registration statement on Form S-1 covering the resale of the Registrable Securities |
| June 11, 2024 | Dr. LaFrance stepped down from his position as the Company's Chief Medical Officer |
| June 24, 2024 | SEC declared effective the registration statement on Form S-1 covering the resale of the Registrable Securities |
| June 25, 2024 | Record date for the Annual Meeting |
| July 5, 2024 | Date for beneficial ownership information |
| July 8, 2024 | Board approved the fourth amendment and restatement of the 2020 Stock Incentive Plan |
| August 15, 2024 | 2024 Annual Meeting of Stockholders |
| 2025 | Annual Meeting of Stockholders |
Keywords
radiotherapeutic, rhenium, obisbemeda, leptomeningeal metastases, glioblastoma, clinical trial, CNSide, stock incentive plan, executive compensation, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.